PDL BioPharma Inc  

(Public, NASDAQ:PDLI)   Watch this stock  
Find more results for Christopher Hart´┐Ż
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 6.38 - 10.26
Open     -
Vol / Avg. 0.00/3.49M
Mkt cap 1.09B
P/E 3.48
Div/yield 0.15/9.01
EPS 1.91
Shares 163.53M
Beta 0.66
Inst. own 90%
Aug 17, 2015
Q2 2015 PDL BioPharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 28, 2015
PDL BioPharma Inc Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
May 6, 2015
Q1 2015 PDL BioPharma Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 PDL BioPharma Inc Earnings Release
Mar 4, 2015
PDL BioPharma Inc at Cowen Health Care Conference
Feb 25, 2015
PDL BioPharma Inc at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 56.44% 55.44%
Operating margin 94.88% 92.94%
EBITD margin - 93.99%
Return on average assets 32.64% 42.79%
Return on average equity 74.29% 112.29%
Employees 10 -
CDP Score - -


932 Southwood Blvd
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


PDL BioPharma, Inc. (PDL) is a biotech company. The Company is engaged in managing a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL is engaged in the discovery of targeted treatments for cancer and immunologic diseases for which it receives royalty revenue. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders. PDL has entered into licensing agreements under its Queen et al. patents with entities that are independently developing or have developed humanized antibodies. The Company receives royalties on net sales of products that are made, used and/or sold prior to patent expiry. Under the licensing agreements, the Company receives a flat-rate or tiered royalty based upon its licensees’ net sales of covered antibodies.

Officers and directors

John P. McLaughlin President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Peter S. Garcia Chief Financial Officer, Vice President
Age: 53
Bio & Compensation  - Reuters
David Montez CPA Chief Accounting Officer, Controller
Age: 41
Bio & Compensation  - Reuters
Christopher Lewis Stone J.D. Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Danny Hart Vice President - Business Development
Age: 39
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 59
Bio & Compensation  - Reuters
Jody S. Lindell Independent Director
Age: 63
Bio & Compensation  - Reuters
Paul W. Sandman Independent Director
Age: 67
Bio & Compensation  - Reuters
Harold E. Selick Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters